Doxorubicin action on mitochondria: relevance to osteosarcoma therapy?
MetadataShow full item record
The mitochondria may very well determine the final commitment of the cell to death, particularly in times of energy stress. Cancer chemotherapeutics such as the anthracycline doxorubicin perturb mitochondrial structure and function in tumour cells, as evidenced in osteosarcoma, for which doxorubicin is used clinically as frontline therapy. This same mechanism of cell inhibition is also pertinent to doxorubicin's primary cause of side-effects, that to the cardiac tissue, culminating in such dire events as congestive heart failure. Reactive oxygen species are partly to blame for this effect on the mitochondria, which impact the electron transport chain. As this review highlights, there is much more to be learnt about the mitochondria and how it is affected by such effective but toxic drugs as doxorubicin in the hope that cancer treatment can be aided by finding ways to preserve mitochondrial number and function in normal cells.
Showing items related by title, author, creator and subject.
A novel Osmium-based compound targets the mitochondria and triggers ROS-dependent apoptosis in colon carcinomaMaillet, A.; Yadav, S.; Loo, Y.; Sachaphibulkij, K.; Pervaiz, Shazib (2013)Engagement of the mitochondrial-death amplification pathway is an essential component in chemotherapeutic execution of cancer cells. Therefore, identification of mitochondria-targeting agents has become an attractive ...
Nucleotropic doxorubicin nanoparticles decrease cancer cell viability, destroy mitochondria, induce autophagy and enhance tumour necrosisFriedhuber, A.; Chandolu, V.; Manchun, S.; Donkor, O.; Sriamornsak, P.; Dass, Crispin (2015)Objective: Doxorubicin (Dox) is used clinically against various neoplasias, but suffers from serious side effects, and for the past three decades, this shortcoming has spurred research towards finding better drug delivery ...
Doxorubicin-induced death in tumour cells and cardiomyocytes: is autophagy the key to improving future clinical outcomes?Tacar, O.; Dass, Crispin (2013)Objectives: Doxorubicin, a commonly used frontline chemotherapeutic agent for cancer, is not without side-effects. The original thinking that the drug causes necrosis in tumours has largely given way to its link with ...